Clinical Trials Logo

Hepatorenal Syndrome clinical trials

View clinical trials related to Hepatorenal Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05434286 Active, not recruiting - Cirrhosis, Liver Clinical Trials

Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Hepatorenal Syndrome-Acute Kidney Injury

Start date: December 15, 2021
Phase:
Study type: Observational

Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF accurately. We will assess IVC dynamics, LV systolic function [LV ejection fraction (EF) & cardiac output (CO)], and diastolic dysfunction (E/e', e' and E/A ratio) and urinary biomarkers (cystatin C and NGAL) in patients with cirrhosis and ACLF with hepatorenal syndrome-acute kidney injury (HRS-AKI).

NCT ID: NCT04460560 Active, not recruiting - Clinical trials for Hepatorenal Syndrome

Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)

INFUSE
Start date: December 11, 2020
Phase: Phase 3
Study type: Interventional

Hepatorenal syndrome-acute kidney injury (HRS-AKI), a potentially reversible renal failure, is a serious, rapidly progressing, often fatal, complication of decompensated cirrhosis. Terlipressin is a synthetic vasopressin analogue that acts as a systemic vasoconstrictor via the vascular vasopressin V1 receptors. In HRS-AKI patients the strong V1 receptor-mediated vasoconstrictor activity of terlipressin, particularly in the splanchnic area, increases effective intravascular volume and mean arterial pressure (MAP), ameliorates renin-angiotensin-aldosterone system and sympathetic nervous system hyperactivity, and improves renal blood flow. The INFUSE trial will evaluate the use of continuous terlipressin infusion in patients on the liver transplant waiting list with HRS-AKI.

NCT ID: NCT01530711 Active, not recruiting - Cirrhosis Clinical Trials

Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response

AMELIORATE
Start date: April 2012
Phase: Phase 4
Study type: Interventional

Observe the effect of terlipressin on renal function in patients with SHR type I adjusting the dose based on hemodynamic response.